Disclosures Dr Dowson has provided consultancy to Shire Pharmaceuticals. Dr Frewin has received honoraria for scientific consultation, chairing meetings and organising training days for Specialty Registrars from Shire Pharmaceuticals.
Version of Record online: 14 AUG 2012
© 2012 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 66, Issue 10, pages 976–983, October 2012
How to Cite
Frewin, R. and Dowson, A. (2012), Headache in essential thrombocythaemia. International Journal of Clinical Practice, 66: 976–983. doi: 10.1111/j.1742-1241.2012.02986.x
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- Issue online: 19 SEP 2012
- Version of Record online: 14 AUG 2012
Headache is frequently reported as one of the neurological manifestations of essential thrombocythaemia (ET) and other myeloproliferative neoplasms. It is associated with considerable morbidity; yet, it is a frequently under-recognised symptom. In patients with ET, headaches may be attributable to the disease, to the prescribed ET treatment, or unrelated to ET. The majority of headaches in ET are self-limiting and can be managed with standard headache therapies such as paracetamol, but it is vital that the clinician managing these conditions is able to recognise the headaches with a more sinister pathology.
In this article, we will review the incidence and management of headaches in ET, whether they are primarily related to the disease or a result of its treatment.
Identification of specific headache types in patients with ET may enable physicians to employ the most effective headache medication. This would enhance the patient-physician relationship, increasing patient compliance and thus reducing the risk of adverse outcomes.